(redirected from Fumaric Acid Ester)
FAéForce Aérienne Belge (Belgian Air Force)
References in periodicals archive ?
The symposium, entitled Treating psoriasis: a matter of renewed experience', will provide an update on oral systemic treatments for patients with moderate-to-severe psoriasis, with a special focus on fumaric acid esters (FAEs) and on the existing clinical experience with their use
Even though fumaric acid esters are increasingly considered to be a suitable, even a firstdine, systemic treatment for moderate to severe psoriasis in some parts of Europe, the evidence supporting their use is sparse and of low quality, according to a report published online in the British Journal of Dermatology.
Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?
cyclosporine, methotrexate, oral retinoids, fumaric acid esters) to control their disease adequately.
Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
Fumaric acid esters possess a unique anti-inflammatory mechanism of action and have been used to treat psoriasis in Germany for over 20 years.
Fumaric acid esters have been used since 1959 in Germany for the treatment of psoriasis, and the proprietary formulation Fumaderm, which contains a mixture of dimethylfumarate and monoethylfumarate salts, has been licensed since 1994 in that country.
John's Institute of Dermatology, London, have enrolled 62 patients with severe psoriasis that did not respond to standard therapies into an open study of Fumaderm, the German formulation of fumaric acid esters.
Therapies that activate a T-helper 2 response, such as biologics and fumaric acid esters, may dampen inflammation over the long term and protect patients from serious diseases, such as diabetes and heart disease.
Fumaric acid esters have been used successfully for decades in Germany to treat psoriasis, but GI side effects have limited their use.
Biologics and fumaric acid esters, the latter an increasingly popular option in Germany and other parts of Europe, may represent safer therapeutic interventions for psoriasis patients with complex comorbid conditions, he said.
Therapies that activate a T-helper 2 response, such as biologics and fumaric acid esters that are available in Germany, may dampen inflammation through mechanisms that, over the long term, protect patients from serious diseases.